Monitoring interstitial m‐THPC‐PDT in vivo using fluorescence and reflectance spectroscopy
暂无分享,去创建一个
Arjen Amelink | H. S. de Bruijn | Bastiaan Kruijt | Angelique van der Ploeg-van den Heuvel | A. Amelink | H. Sterenborg | D. Robinson | A. van der Ploeg-van den Heuvel | Dominic J. Robinson | Henriette S. de Bruijn | Henricus J.C.M. Sterenborg | B. Kruijt
[1] Thomas H. Foster,et al. In Vivo mTHPC Photobleaching in Normal Rat Skin Exhibits Unique Irradiance-dependent Features¶ , 2002, Photochemistry and photobiology.
[2] M. Menke-Pluymers,et al. Intraoperatively assessed optical properties of malignant and healthy breast tissue used to determine the optimum wavelength of contrast for optical mammography. , 2004, Journal of biomedical optics.
[3] Arjen Amelink,et al. Confidence intervals on fit parameters derived from optical reflectance spectroscopy measurements. , 2008, Journal of biomedical optics.
[4] Stefan Andersson-Engels,et al. In vivo measurement of parameters of dosimetric importance during interstitial photodynamic therapy of thick skin tumors. , 2006, Journal of biomedical optics.
[5] L. Lilge,et al. Implicit and explicit dosimetry in photodynamic therapy: a New paradigm , 1997, Lasers in Medical Science.
[6] Daniel J. Gould,et al. Photodynamic therapy using meta‐tetrahydroxyphenylchlorin (Foscan®) for the treatment of vulval intraepithelial neoplasia , 2004, The British journal of dermatology.
[7] L. Kunz,et al. Correlation of real-time haemoglobin oxygen saturation monitoring during photodynamic therapy with microvascular effects and tissue necrosis in normal rat liver , 2004, British Journal of Cancer.
[8] E. Hull,et al. Porphyrin Bleaching and PDT-induced Spectral Changes are Irradiance Dependent in ALA-sensitized Normal Rat Skin In Vivo¶ , 2001, Photochemistry and photobiology.
[9] P Baas,et al. Foscan® uptake and tissue distribution in relation to photodynamic efficacy , 2003, British Journal of Cancer.
[10] T. Foster,et al. Effects of Fluence Rate on Cell Survival and Photobleaching in Meta-Tetra-(hydroxyphenyl)chlorin–photosensitized Colo 26 Multicell Tumor Spheroids¶ , 2001, Photochemistry and photobiology.
[11] Thomas H. Foster,et al. Portable instrument that integrates irradiation with fluorescence and reflectance spectroscopies during clinical photodynamic therapy of cutaneous disease , 2006 .
[12] S. Nighswander-Rempel,et al. Relative Contributions of Hemoglobin and Myoglobin to Near-Infrared Spectroscopic Images of Cardiac Tissue , 2005, Applied spectroscopy.
[13] Lise Lyngsnes Randeberg,et al. Monitoring of hexyl 5-aminolevulinate-induced photodynamic therapy in rat bladder cancer by optical spectroscopy. , 2008, Journal of biomedical optics.
[14] Jarod C Finlay,et al. Hemoglobin oxygen saturations in phantoms and in vivo from measurements of steady-state diffuse reflectance at a single, short source-detector separation. , 2004, Medical physics.
[15] I. Tan,et al. Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. , 2003, Archives of otolaryngology--head & neck surgery.
[16] Arjen Amelink,et al. Optical biopsy of breast tissue using differential path-length spectroscopy , 2005, Physics in medicine and biology.
[17] A. Curnow,et al. Oxygen monitoring during 5-aminolaevulinic acid induced photodynamic therapy in normal rat colon. Comparison of continuous and fractionated light regimes. , 2000, Journal of photochemistry and photobiology. B, Biology.
[18] Arjen Amelink,et al. Measurement of the local optical properties of turbid media by differential path-length spectroscopy. , 2004, Applied optics.
[19] K. Masuda,et al. Determination of myoglobin concentration in blood-perfused tissue , 2008, European Journal of Applied Physiology.
[20] H. Oppelaar,et al. Photodynamic Therapy for Malignant Mesothelioma: Preclinical Studies for Optimization of Treatment Protocols¶ , 2001, Photochemistry and photobiology.
[21] C. Hadjur,et al. Spectroscopic studies of photobleaching and photoproduct formation of meta(tetrahydroxyphenyl)chlorin (m-THPC) used in photodynamic therapy. The production of singlet oxygen by m-THPC , 1998 .
[22] Brian W. Pogue,et al. Estimation of Oxygen Distribution in RIF-1 Tumors by Diffusion Model-Based Interpretation of Pimonidazole Hypoxia and Eppendorf Measurements , 2001, Radiation research.
[23] M Emberton,et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer , 2006, Lasers in surgery and medicine.
[24] H. S. de Bruijn,et al. Monitoring In Situ Dosimetry and Protoporphyrin IX Fluorescence Photobleaching in the Normal Rat Esophagus During 5‐Aminolevulinic Acid Photodynamic Therapy ¶ , 2003, Photochemistry and photobiology.
[25] M G Nichols,et al. The Mechanism of Photofrin Photobleaching and Its Consequences for Photodynamic Dosimetry , 1997, Photochemistry and photobiology.
[26] Quantitative fluorescence spectroscopy in turbid media using fluorescence differential path length spectroscopy. , 2008, Journal of biomedical optics.
[27] Michael S Patterson,et al. Relationship Between mTHPC Fluorescence Photobleaching and Cell Viability During In Vitro Photodynamic Treatment of DP16 Cells¶ , 2002, Photochemistry and photobiology.
[28] P Baas,et al. Photodynamic therapy with meta‐tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study , 2001, The British journal of dermatology.
[29] Michael J. Emanuele,et al. Treatment-Induced Changes in Tumor Oxygenation Predict Photodynamic Therapy Outcome , 2004, Cancer Research.
[30] In vivo fluence rate measurements during Foscan-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator. , 2006, Journal of biomedical optics.
[31] D. Vernon,et al. Photodynamic therapy effect of m-THPC (Foscan®) in vivo: correlation with pharmacokinetics , 2003, British Journal of Cancer.
[32] J. Holloszy,et al. Augmentation of skeletal muscle myoglobin by a program of treadmill running. , 1967, The American journal of physiology.
[33] Hubert van den Bergh,et al. In-vivo measurement of fluorescence bleaching of meso-tetra hydroxy phenyl chlorin (mTHPC) in the esophagus and the oral cavity , 1995, European Conference on Biomedical Optics.
[34] Kai Zhang,et al. Techniques for delivery and monitoring of TOOKAD(WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities , 2005, SPIE BiOS.
[35] I. Tan,et al. Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx , 2007, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.
[36] L. Kunz,et al. Intracellular Photobleaching of 5,10,15,20-Tetrakis(m-hydroxyphenyl) chlorin (Foscan®) Exhibits a Complex Dependence on Oxygen Level and Fluence Rate¶ , 2002, Photochemistry and photobiology.
[37] Tayyaba Hasan,et al. Photobleaching‐based Dosimetry Predicts Deposited Dose in ALA‐PpIX PDT of Rodent Esophagus , 2007, Photochemistry and photobiology.
[38] T Theodossy,et al. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer , 2004, British Journal of Cancer.
[39] Jarod C Finlay,et al. Real-time In Situ Monitoring of Human Prostate Photodynamic Therapy with Diffuse Light , 2006, Photochemistry and photobiology.
[40] Stanley B. Brown,et al. Fluorescence Photobleaching of ALA‐induced Protoporphyrin IX during Photodynamic Therapy of Normal Hairless Mouse Skin: The Effect of Light Dose and Irradiance and the Resulting Biological Effect , 1998, Photochemistry and photobiology.
[41] Arjen Amelink,et al. Monitoring ALA‐induced PpIX Photodynamic Therapy in the Rat Esophagus Using Fluorescence and Reflectance Spectroscopy , 2008, Photochemistry and photobiology.